ClinicalTrials.gg
CompletedNCT02244229Updated Sep 19, 2014

Study to Evaluate the Therapeutic Action of Tamsulosin and Finasteride in Symptomatic Benign Prostatic Hyperplasia (BPH) Patients

A Phase 4 interventional study of Tamsulosin and Finasteride in Prostatic Hyperplasia, sponsored by Boehringer Ingelheim. Completed. Open to male participants aged 50 Years to 80 Years. Per ClinicalTrials.gov, last updated 2014-09-19.

Sponsored by Boehringer Ingelheim · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
403
Allocation
Randomized
Ages
50 Years to 80 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 48 studies testing tamsulosin in Prostatic Hyperplasia — 8 open to participants now, 8 under way, 1 of them phase 3. Tamsulosin · Prostatic Hyperplasia.

Enrollment
14th of 48
403 · median 118
Started
1998
with 2 others
Phase 4
17 of 48
4 open now
Registered
19th of 48
by date
Lead sponsor
5 of 48
Boehringer Ingelheim

Among the 48 studies testing tamsulosin in Prostatic Hyperplasia, this one is the 14th largest by enrollment, is one of 3 that started in 1998, is one of 17 in phase 4, and was the 19th registered.

Prostatic Hyperplasia

828 studies on the registry are indexed under Prostatic Hyperplasia; 179 are open to participants now.

Browse Prostatic Hyperplasia studies →

Open to participants now

8 of the 48 studies testing tamsulosin in Prostatic Hyperplasia are open now, in 3 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About tamsulosin

Tamsulosin: first FDA approval 1997 (FLOMAX). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 102 Prostatic Hyperplasia studies recruiting now, 70 (69%) set no upper age limit and 4 (4%) stop at 75 or younger; 7 take children under 18; 7 take healthy volunteers.

This study: 50 Years to 80 Years · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 48 studies testing tamsulosin in Prostatic Hyperplasia, or all of them as a file.
02

Study summary

Study to evaluate the therapeutic effect of tamsulosin and finasteride in symptomatic BPH patients, two medications indicated in BPH belonging to two different pharmacological classes, as evaluated from the point of view of patient's perception of his pathological condition and of the impact of the disease on general health and quality of life

03

Conditions studied

  • Prostatic Hyperplasia

Browse trials for

04

Who can participate

Ages eligible
50 Years to 80 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male out-patients aged 50-80 years
  • IPSS >= 13 at Visit 1
  • Qmax: 4-15 ml/sec at Visit 2
  • Residue urinary volume > 400 ml as evaluated by ultrasonography
  • SPI >= 7 at Visit 2
  • Prostate Specific Antigen (PSA) value \< 3 ng/ml at Visit 1, or of 3-10 ng/ml provided that prostate cancer is ruled out on the basis of the usual diagnostic procedures performed at each Centre
  • Written

Exclusion criteria

Exclusion Criteria:

Patients with known history or diagnosis at the time of the screening visit of the following conditions that could influence the end-points of the study:

  • Urological disturbances

    • Medical history of pelvic surgery; palpable bladder at the physical examination, or residue urinary volume > 400 ml; known neurological bladder disorder, bladder neck stenosis, urethral stricture, bladder or prostatic cancer, bladder stone, severe diverticulum of the bladder, symptomatic urinary tract infection during the last month, or recurrent urinary tract infections (more than 2 during the last year); hematuria of unknown origin; diseases that may affect micturition (e.g. diabetes mellitus)
  • Cardiovascular diseases - The following cardiovascular diseases if occurred in the last 6 months:

    • Myocardial infarction
    • Unstable angina
    • ventricular arrhythmias
    • Heart failure ( classes III/IV)
    • Orthostatic hypotension
    • Cerebral stroke
  • Neurological diseases

    • such as senile dementia, multiple sclerosis, Parkinson's disease, psychiatric disturbances, if their severity could have prevented the correct performance of the trial
  • Hepatic or renal insufficiency

    • (Biochemistry values 15% outside normal laboratory ranges and regarded as clinically relevant by investigator)
  • Clinically significant abnormalities in the results of hematologic and biochemical tests performed on blood samples drawn at the screening visit
  • Patients who are taking or have been taking α-blockers for BPH or for hypertension or phytotherapy for BPH in the previous 6 weeks
  • Patients who are taking or have been taking finasteride in the last 6 months
  • Patients who require concomitant drugs which could influence the pharmacodynamic or pharmacokinetic properties of tamsulosin. In particular: alpha-blockers and mixed alpha-beta blockers, alpha- agonists, anti-cholinergics
  • Patient who are or have been taking part in a clinical study in the previous 3 months
  • Patients who have or allergic reactions to previously prescribed alpha-blocker(s) or to finasteride
  • Patients judged by the investigator to be inappropriate for inclusion in the study
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
403 participants (actual)

Study arms

  • Experimental
    Tamsulosin

    Drug: Tamsulosin · Drug: Placebo

  • Active comparator
    Finasteride

    Drug: Finasteride · Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Change from baseline in Symptom Problem Index (SPI) by means of validated patient questionnaire

    Time frame: Baseline, after 26 weeks of treatment

Secondary outcomes

  1. Change in Symptom Problem Index (SPI) - by means of validated patient questionnaire

    Time frame: up to 52 weeks

  2. Change in International Prostatic Symptom Score (IPSS)

    questionnaire for the self-evaluation of urinary symptoms

    Time frame: up to 52 weeks

  3. Change in Qmax by means of free flow uroflowmetry

    Time frame: up to 52 weeks

  4. Number of patients who withdrew due to inefficacy

    Time frame: up to 52 weeks

  5. Number of patients with adverse events

    Time frame: up to 54 weeks

  6. Number of patients with abnormal changes in laboratory parameters

    Time frame: up to 52 weeks

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 1998 and a primary completion of Nov 2000. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 18, 2014
First posted
Sep 19, 2014
Start
Apr 1998
Primary completionActual
Nov 2000
Last update
Sep 19, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 19, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02244229
Responsible party
Sponsor
First posted
Sep 19, 2014
Start date
Apr 1998
Primary completion
Nov 2000
Last update
Sep 19, 2014
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tamsulosin

Start the discussion